Want to see BGMS full AI Analyst Report?
BGMS Stock Chart & Stats
$0.92
<$0.01(1.08%)
At close: 4:00 PM EDT
$0.92
<$0.01(1.08%)
Day’s Range― - ―
52-Week Range$0.57 - $8.82
Previous Close$0.92
Volume18.36K
Average Volume (3M)473.94K
Market Cap
$6.00M
Enterprise Value$1.30
Total Cash (Recent Filing)$3.79M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.64
Shares Outstanding6,622,794
10 Day Avg. Volume1,252,948
30 Day Avg. Volume473,939
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.47
Price to Sales (P/S)4.33
P/FCF Ratio-0.68
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-268.8
Revenue Forecast (FY)$100.00K
Bulls Say, Bears Say
Bulls Say
Revenue GrowthImproving revenue indicates stronger commercialization and customer adoption. Continued growth would provide a larger base for operating leverage, particularly as the company focuses on fire safety and related environmental services.
Low Financial LeverageA debt-light balance sheet limits creditor pressure and interest obligations, giving BGMS greater flexibility to fund its strategic transition. Positive equity also provides a stronger base than a highly leveraged structure, although losses remain a risk.
Strategic Business RefocusThe shift from biopharmaceuticals toward fire safety and environmental services may create a more focused operating model. Combining regulated safety, waste treatment and compliance-driven offerings could diversify revenue and deepen customer relationships.
Bears Say
Severe UnprofitabilityVery low gross profitability and operating losses exceeding revenue show that BGMS has not yet established a scalable cost structure. Sustained losses could limit reinvestment capacity and require additional financing before growth translates into durable earnings.
Persistent Cash BurnNegative operating and free cash flow means the business is not funding operations internally. Although the burn improved from 2025, continued cash consumption keeps BGMS dependent on external capital and raises execution risk during its strategic transition.
Material Shareholder DilutionThe proposed all-stock acquisition could substantially reduce existing shareholders' ownership and economic influence if completed. Recent equity financing further demonstrates reliance on issuing shares, creating an ongoing dilution risk while profitability and cash generation remain weak.
Bio Green Med Solution News
BGMS FAQ
What was Bio Green Med Solution’s price range in the past 12 months?
Bio Green Med Solution lowest stock price was $0.57 and its highest was $8.82 in the past 12 months.
What is Bio Green Med Solution’s market cap?
Bio Green Med Solution’s market cap is $6.00M.
When is Bio Green Med Solution’s upcoming earnings report date?
Bio Green Med Solution’s upcoming earnings report date is Nov 18, 2026 which is in 88 days.
How were Bio Green Med Solution’s earnings last quarter?
Bio Green Med Solution released its earnings results on Aug 12, 2026. The company reported -$0.076 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Bio Green Med Solution overvalued?
According to Wall Street analysts Bio Green Med Solution’s price is currently Overvalued.
Does Bio Green Med Solution pay dividends?
Bio Green Med Solution pays a Notavailable dividend of $0.15 which represents an annual dividend yield of N/A. See more information on Bio Green Med Solution dividends here
What is Bio Green Med Solution’s EPS estimate?
Bio Green Med Solution’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bio Green Med Solution have?
Bio Green Med Solution has 6,622,794 shares outstanding.
What happened to Bio Green Med Solution’s price movement after its last earnings report?
Bio Green Med Solution reported an EPS of -$0.076 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.217%.
Which hedge fund is a major shareholder of Bio Green Med Solution?
Currently, no hedge funds are holding shares in BGMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bio Green Med Solution
Bio Green Med Solution, Inc. (BGMS) operates as a multifaceted company, with active involvement in both the fire protection and biopharmaceutical industries. The organization recently broadened its capabilities by completing the acquisition of Fitters Sdn. Bhd., a Malaysian firm known for its fire safety products and services. BGMS is committed to driving progress in biopharmaceutical research and developing cutting-edge fire safety solutions, striving to deliver enduring value to its investors.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Rein Therapeutics
―
Bluejay Diagnostics
―
Neuphoria Therapeutics
―
Ownership Overview
45.19% Insiders
0.03% Mutual Funds
<0.01% Other Institutional Investors
54.78% Public Companies and
Individual Investors